Celldex Therapeutics (CLDX)
(Delayed Data from NSDQ)
$35.38 USD
-1.54 (-4.17%)
Updated May 28, 2024 04:00 PM ET
After-Market: $35.38 0.00 (0.00%) 6:10 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
Celldex Therapeutics, Inc. [CLDX]
Reports for Purchase
Showing records 201 - 220 ( 411 total )
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Feb. 1This report contains brief updates on the following: SRPT, RGLS, BMRN, CBYL, CLDX, EPRS, LXRX, PCRX, PRTA, PTCT, RPTP, TTPH, RARE, VTAE, ICPT, CERU, FCSC, GBT, TSRO, TRVN, IRWD, MRTX, DNAI, XNCR. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ReACT Update Should Receive Good ReACTions; Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Nov. 23
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q EPS, Broad Pipeline continues to Progress
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SITC 2015 Takeaways; CLDX - GALE New Data; TIL Progress Bodes Well for LBIO
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q15 Results; Looking to Build Excitement Again; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotech Names for the Turn and the Long Haul
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Celldex Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2:15 EPS; Rintega Filing to Wait for ACT IV Study Data; PT Lowered to $24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D